Biotech

All Articles

Regeneron's Opdualag competitor shows 57% reaction rate

.Regeneron is back with lasting follow-up for its LAG-3 prevention as well as PD-1 prevention combo ...

AstraZeneca posts data on internal rivals to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early check out the efficiency of its own in-house antibody-drug c...

iTeos- GSK's TIGIT celebrity shows purposeful renovation

.After declaring a stage 3 launch based upon favorable midstage results, iTeos and also GSK are fina...

More joint FDA can increase unusual disease R&ampD: record

.The FDA ought to be actually much more available and also collective to discharge a rise in approva...

Zenas, MBX, Bicara scalp to Nasdaq in hot day for biotech IPOs

.It's an unusually busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicara Reh...

Atea's COVID antiviral falls short to stop hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has stopped working one more COVID-19 test, however the biotech sti...

Neurocrine's offer to save mental illness possibility falls short

.Neurocrine Biosciences' schizophrenia system pivot has neglected. The biotech was actually unable t...

Sanofi pays for $110M upfront for late-stage radioligand therapy

.Sanofi has actually brought in a late entrance to the radioligand gathering, paying out one hundred...

F 2G raises $100M for second effort to receive brand new antifungal to market

.After F2G's very first attempt to get a new lesson of antifungal to market was actually wrecked due...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 courses surrounded by earnings tensions

.Moderna has actually promised to reduce R&ampD investing by $1.1 billion by 2027. The selection to ...